January 6, 2022
During the 63rd ASH Annual Meeting and Exposition, Know AML spoke with Sabine Haggenburg, Amsterdam UMC, Amsterdam, NL. We asked, Should COVID-19 vaccination be postponed after AML therapy?
Haggenburg begins by discussing COVID-19 risks to AML patients, and the responses to vaccinations that have been observed so far. However, she highlights that vaccination does not protect patients taking hypomethylating agents (HMAs), such as azacitidine and decitabine.
What does real-world data tell us about frontline therapy with CPX-351 vs Ven + Aza?
Alexander E. Perl
January 21, 2022
Do patients enrolled in clinical trials really represent the AML population?
December 17, 2021